Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

被引：2
|
作者：
Li, Dunhui [1 ,2 ,3 ]
Mastaglia, Frank L. [1 ,2 ]
Yau, Wai Yan [1 ]
Chen, Shengdi [4 ,5 ]
Wilton, Steve D. [1 ,2 ]
Akkari, Patrick A. [1 ,2 ,6 ]
机构：
[1] Univ Western Australia, Perron Inst Neurol & Translat Sci, 8 Verdun St, Nedlands, WA 6009, Australia
[2] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Murdoch, WA, Australia
[3] Zhengzhou Univ, Coll Nursing & Hlth, Zhengzhou, Peoples R China
[4] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China
[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Inst Neurol, Sch Med, Shanghai, Peoples R China
[6] Duke Univ, Dept Neurol, Durham, NC USA
来源：
MOVEMENT DISORDERS | 2022年 / 37卷 / 11期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1002/mds.29201
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：2184 / 2190
页数：7
相关论文
共 50 条
  • [41] LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model
    Zhao, Hien Tran
    John, Neena
    Delic, Vedad
    Ikeda-Lee, Karli
    Kim, Aneeza
    Weihofen, Andreas
    Swayze, Eric E.
    Kordasiewicz, Holly B.
    West, Andrew B.
    Volpicelli-Daley, Laura A.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2017, 8 : 508 - 519
  • [42] Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease
    Hoekstra, Jake G.
    Montine, Kathleen S.
    Zhang, Jing
    Montine, Thomas J.
    ALZHEIMERS RESEARCH & THERAPY, 2011, 3 (03):
  • [43] Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease
    Jake G Hoekstra
    Kathleen S Montine
    Jing Zhang
    Thomas J Montine
    Alzheimer's Research & Therapy, 3
  • [44] Reusable solid-phase supports for oligonucleotides and antisense therapeutics
    Pon, RT
    Yu, SY
    Guo, ZQ
    Deshmukh, R
    Sanghvi, YS
    JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 2001, (20): : 2638 - 2643
  • [45] Antisense Oligonucleotides as Therapeutics for Difficult-to-Drug Targets in Oncology
    Denker, Andrew
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (11)
  • [46] Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics
    Ramasamy, Thiruganesh
    Ruttala, Hima Bindu
    Munusamy, Shankar
    Chakraborty, Nilay
    Kim, Jong Oh
    JOURNAL OF CONTROLLED RELEASE, 2022, 352 : 861 - 878
  • [47] Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
    Le, Bao T.
    Raguraman, Prithi
    Kosbar, Tamer R.
    Fletcher, Susan
    Wilton, Steve D.
    Veedu, Rakesh N.
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2019, 14 : 142 - 157
  • [48] Gapmer Oligonucleotides: Sugar-Modified Wings to Antisense Therapeutics
    Rungta, Pallavi
    Mangla, Priyanka
    Sharma, Vivek K.
    Singh, Sunil K.
    Chauhan, Aman
    Masram, Dhanraj T.
    Senapati, Nihar Nalini
    Prasad, Ashok K.
    TRENDS IN CARBOHYDRATE RESEARCH, 2015, 7 (03) : 28 - 43
  • [49] RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
    Bajan, Sarah
    Hutvagner, Gyorgy
    CELLS, 2020, 9 (01)
  • [50] Molecular Construction of Sulfonamide Antisense Oligonucleotides
    Korotkovs, Valerijs
    Reichenbach, Linus F.
    Pescheteau, Clementine
    Burley, Glenn A.
    Liskamp, Rob M. J.
    JOURNAL OF ORGANIC CHEMISTRY, 2019, 84 (17): : 10635 - 10648
12345